logo
Share SHARE
FONT-SIZE Plus   Neg

Threshold Pharma's TH-302 Receives EC's Orphan Drug Designation

Threshold Pharmaceuticals, Inc. (THLD) Friday said the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted drug, for the treatment of soft tissue sarcoma.

Soft tissue sarcoma is an aggressive form of cancer and there is a significant unmet medical need for the condition. TH-302 was designed to selectively target hypoxic regions within tumors, which are believed not effectively treated with current therapy.

Threshold is currently conducting a pivotal Phase 3 study in soft tissue sarcoma, comparing TH-302 in combination with doxorubicin against single agent doxorubicin.

"The Orphan Drug Designation was granted as early studies of TH-302 have shown that it might be of significant benefit for patients with soft tissue sarcoma when combined with doxorubicin," said Barry Selick, Ph.D., CEO of Threshold.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walt Disney Co. has threatened to pull its programming from cable distributor Altice USA Inc. if the two companies are unable to reach a new deal before the end of September. The current contract between the two companies expires at the end of this month. Jaguar Land Rover, Britain's biggest car maker, is eyeing potential acquisitions of international automakers, Bloomberg reported Monday, citing people with knowledge of the matter. Jaguar Land Rover, owned by India's Tata Motors Ltd., has reportedly been holding internal discussion on acquiring other brands in order to diversify its range of vehicles. Target Corp. said Monday that it plans to raise minimum hourly wage for all its workers to $11 in October, marking its third wage increase in three years. The discount-store operator also said it is committed to increasing the minimum hourly wage to $15 by the end of 2020.
comments powered by Disqus
Follow RTT